Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03761914 · OUTCOME

Progression-free Survival (PFS) - Kaplan Meier Estimate

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · Source last updated 2024-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
33 months

What was measured

Time from enrollment to date of first confirmed disease progression or death whichever occurred earlier

Analysis population: Participants who received at least one dose of pembrolizumab (galinpepimut-S + pembrolizumab); mITT population. Patients only enrolled in the Ovarian Cancer (OvC) arm. One subject from the Colorectal Cancer (CRC) arm enrolled but discontinued before efficacy can be assessed. The other arms/groups were removed from this study.

Groups in this outcome

Ovarian Cancer (OvC)

* Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab

Colorectal Cancer

One subject enrolled but discontinued before efficacy can be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ovarian Cancer (OvC)16
Colorectal Cancer0

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Ovarian Cancer (OvC)2.9Not reported2.05.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.0
        upper Limit
        5.6
        value
        2.9
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Time from enrollment to date of first confirmed disease progression or death whichever occurred earlier
dispersion Type
95% Confidence Interval
groups
  1. description
    * Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy * Galinpepimut-S + Montanide + GM-CSF + pembrolizumab
    id
    OG000
    title
    Ovarian Cancer (OvC)
  2. description
    One subject enrolled but discontinued before efficacy can be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety.
    id
    OG001
    title
    Colorectal Cancer
param Type
MEDIAN
population Description
Participants who received at least one dose of pembrolizumab (galinpepimut-S + pembrolizumab); mITT population. Patients only enrolled in the Ovarian Cancer (OvC) arm. One subject from the Colorectal Cancer (CRC) arm enrolled but discontinued before efficacy can be assessed. The other arms/groups were removed from this study.
reporting Status
POSTED
time Frame
33 months
title
Progression-free Survival (PFS) - Kaplan Meier Estimate
type
OTHER_PRE_SPECIFIED
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice